NCT03187431

Role of Stem Cell Therapy in Interstitial Pulmonary Fibrosis

Mesenchymal Stem Cell as Therapeutic Modality in Interstitial Pulmonary Fibrosis

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Assiut University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Currently, the application status of MSCs as treatment modalities in IPF is still in its infancy and remains exploratory. Although a number of safety and efficacy clinical trials of MSCs as therapeutic options in immune-mediated and cardiac diseases have already been published with tantalizing results, to our disappointment, pulmonary and critical care medicine have traditionally lagged behind other therapeutic and research fields including hematology, gastroenterology and cardiology in translational studies of the use of reparative cells

Conditions

• Stem Cell Transplant Complications

Interventions

Type	Name	Description
BIOLOGICAL	autologous bone marrow mesenchymal stem cells	intravenous infusion

Timeline

• Start date: 2017-12-11
• Primary completion: 2018-10-01
• Completion: 2018-12-01
• First posted: 2017-06-15
• Last updated: 2017-06-15